Companies › Harbour BioMed (Guangzhou)
1 active drug program in 1 registered trial: 1 Phase 1; Oncology.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| HBM4003 (Porustobart) Anti-CEACAM5 antibody | CEACAM5 | Phase 1 | Solid Tumors | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05167071 | HBM4003 (Porustobart) | Phase 1 | Solid Tumors | Oncology | Sep 2025 |
Chongqing Precision Biotech Beijing Biotech Merck KGaA A2 Biotherapeutics Roche Bristol-Myers Squibb LaNova Medicines Genmab Kivu Bioscience Fortvita Biologics (USA)Inc.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.